| Derechos | Preview | Fecha Public. | Título | Autor(es) | Tipo |
| closedAccess |  | 15-jun-2020 | A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study | Gavilá, J.; Haba, J. De La; Bermejo, Begoña; Rodríguez-Lescure, A.; Antón, Andrés; Ciruelos, Eva María; Brunet, J.; Muñoz-Couselo, E.; Santisteban, Marta; Rodríguez Sánchez, C. A.; Santaballa, A.; Sánchez Rovira, P.; Garcia Saenz, J.; Ruiz-Borrego, Manuel; Guerrero‐Zotano, Ángel; Huerta, M.; Cotes-Sanchís, A.; Romera, J. Lao; Aguirre, E.; Cortés, Javier; Llombart, Antonio | artículo |
| openAccess |  | 2-may-2023 | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer | Cejuela, Mónica; Gil-Torralvo, Ana; Castilla, María Ángeles CSIC; Domínguez, María Ángeles; Falcón, Alejandro; Benavent, Marta CSIC ORCID; Molina-Pinelo, Sonia CSIC ORCID; Ruiz-Borrego, Manuel; Salvador-Bofill, Javier CSIC ORCID | artículo |
| openAccess |  | 2019 | Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series | Picornell, A. C.; Echevarria, I.; Álvarez, E.; López-Tarruella, S.; Jerez, Y.; Hoadley, K.; Parker, J. S.; Monte-Millán, M. del; Ramos-Medina, R.; Gayarre, Javier CSIC ORCID; Ocaña, I.; Cebollero, M.; Massarrah, T.; Moreno, Fernando CSIC ORCID; García‐Sáenz, José Ángel; Gómez Moreno, H.; Ballesteros, A.; Ruiz-Borrego, Manuel; Perou, C. M.; Martín, M. | artículo |
| closedAccess |  | feb-2020 | Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients | Cortés, Javier; Ciruelos, Eva María; Pérez-García, José Manuel; Albanell, Joan; García-Estévez, Laura; Ruiz-Borrego, Manuel; Espinosa, Ruth; Gallegos, Isabel; González, Santiago; Álvarez, Isabel; Llombart, Antonio | artículo de revisión |
| openAccess |  | 16-sep-2020 | EDIL3 promotes epithelial–mesenchymal transition and paclitaxel resistance through its interaction with integrin αVβ3 in cancer cells | Gasca Bellido, Jessica; Flores, M. Luz CSIC; Jiménez-Guerrero, Rocío CSIC ORCID; Sáez, María Eugenia; Barragán, Isabel; Ruiz-Borrego, Manuel; Tortolero, María; Romero, Francisco; Sáez, Carmen CSIC ORCID; Japón, Miguel A. CSIC ORCID | artículo |
| closedAccess |  | 2019 | Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study | Ocaña, Alberto; Gil-Martín, Marta; Antolín, Silvia; Atienza, María; Montaño, Álvaro; Ribelles, Nuria; Urruticoechea, Ander; Falcón, Alejandro; Pernas, Sonia; Orlando, Javier; Montero, Juan Carlos CSIC ORCID; Escudero, María José; Benito, Sara; Caballero, Rosalía; Carrasco, Eva; Rojo, Federico; Pandiella, Atanasio CSIC ORCID CVN ; Ruiz-Borrego, Manuel | artículo |
| openAccess |  | sep-2020 | Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial | Barcenas, C. H.; Hurvitz, S. A.; Di Palma, J. A.; Bose, R.; Chien, A. J.; Iannotti, N.; Marx, G.; Brufsky, A.; Litvak, A.; Ibrahim, E.; Alvarez, R. H.; Ruiz-Borrego, Manuel; Chan, N.; Manalo, Y.; Kellum, A.; Trudeau, M.; Thirlwell, M.; Garcia Saenz, J.; Hunt, David W.; Bryce, R.; McCulloch, L.; Rugo, H. S.; Tripathy, D.; Chan, A. | artículo |
| openAccess |  | 7-jul-2016 | Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer | Gasca Bellido, Jessica; Flores, M. Luz CSIC; Giráldez, Servando; Ruiz-Borrego, Manuel; Tortolero, María; Romero, Francisco; Japón, Miguel A. CSIC ORCID; Sáez, Carmen CSIC ORCID | artículo |
| openAccess |  | 3-oct-2013 | Prognostic value of CtIP/RBBP8 expression in breast cancer | Soria-Bretones, Isabel CSIC; Sáez, Carmen CSIC ORCID; Ruiz-Borrego, Manuel; Japón, Miguel A. CSIC ORCID; Huertas Sánchez, Pablo CSIC ORCID | artículo |
| closedAccess |  | 2019 | Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial) | Aapro, Matti; Ruiz-Borrego, Manuel; Hegg, Roberto; Kukielka-Budny, Bozena; Morales, Serafin; Cinieri, Saverio; Freitas-Junior, Ruffo; García-Estévez, Laura; Szombara, Ewa; Santos Borges, Giuliano; Passalacqua, Rodolfo; Hervieu, Helene; Groc, Melanie; Villanova, Gustavo | artículo |
